Company: EDSA
Filing Date: 2025-03-04
Form Type: S-3
Source: 0001171843-25-001239
Chunk: 11

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-04
Form: S-3
Chunk 11
---
, that except as may otherwise be indicated in the footnotes to the table below, the Selling
Shareholders have sole voting and dispositive power with respect to the common shares reported as beneficially owned by it. Because the
Selling Shareholders identified in the table may sell some or all of the common shares beneficially owned by it and covered by this prospectus,
and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the common shares, no
estimate can be given as to the number of common shares available for resale hereby that will be held by the Selling Shareholders upon
termination of this offering. In addition, the Selling Shareholders may have sold, transferred or otherwise disposed of, or may sell,
transfer or otherwise dispose of, at any time and from time to time, the common shares they beneficially own in transactions exempt from
the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) after the date on which they
provided the information set forth in the table below. We have, therefore, assumed for the purposes of the following table, that the Selling
Shareholders will sell all of the common shares owned beneficially by it that are covered by this prospectus, but will not sell any other
common shares that they presently own. The Selling Shareholders or any persons (entities or natural persons) who have control over the
Selling Shareholders, except as disclosed below, have not held any position or office, or has otherwise had a material relationship, with
us or any of our subsidiaries within the past three years other than as a result of the ownership of our common shares or other securities.

Under the terms of certain securities
held by the Selling Shareholders, a Selling Shareholder may not exercise or convert such securities to the extent such exercise or conversion
would cause such Selling Shareholder, together with its affiliates and attribution parties, to beneficially own a number of common shares
which would exceed 4.99%, 9.99% or 19.99%, as applicable, of our then outstanding common shares following such exercise or conversion,
excluding for purposes of such determination common shares issuable upon exercise or conversion of such securities which have not been
exercised or converted. The number of shares in the second and fourth columns do not reflect this limitation, but the percentages set
forth in the fifth column give effect to such limitations. The Selling Shareholders may sell all, some or none of their shares